Summary of PROGENICS PHARMACEUTICALS INC

Search - Finance Home - Yahoo! - Help

Quotes & Info

Enter Symbol(s):
e.g. YHOO, ^DJI

Symbol Lookup | Financial Search

PGNX > SEC Filings for PGNX > Form 8-K on 23-Jul-2009

All Recent SEC Filings

Show all filings for PROGENICS PHARMACEUTICALS INC | Request a Trial to NEW EDGAR Online Pro

Form 8-K for PROGENICS PHARMACEUTICALS INC

23-Jul-2009

Other Events

Item 8.01. Other Events.

Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), with which Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) collaborates in the development and commercialization of RELISTOR®, has informed Progenics that global net sales of RELISTOR for the second quarter of 2009 were $3.2 million, a 74% increase from the first quarter of 2009. Global net sales for the first half of 2009 were $5.1 million.

Add PGNX to Portfolio

Set Alert

Email to a Friend

Get SEC Filings for Another Symbol: Symbol Lookup

Quotes & Info for PGNX - All Recent SEC Filings

Sign Up for a Free Trial to the NEW EDGAR Online Pro
Detailed SEC, Financial, Ownership and Offering Data on over 12,000 U.S. Public Companies.
Actionable and easy-to-use with searching, alerting, downloading and more.
Request a Trial Sign Up Now

Copyright © 2010 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.